Advertisement News Archives - Page 4 of 4889 - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

News

January 18, 2019

Vaccinex completes enrollment for SIGNAL Huntington’s disease trial

Vaccinex has completed subject enrollment for the SIGNAL trial, which is a phase 2, multi-center, randomized, double-blind, placebo controlled study in subjects with early manifest and late prodromal Huntington’s disease (HD) to assess the safety, tolerability, pharmacokinetics, and efficacy of VX15/2503 (pepinemab).

Vaccinex completes enrollment for SIGNAL Huntington’s disease trial